Purging of stem cell products
AssigneeCanji, Inc.
InventorJames E. Talmadge
Life of this patent
Estimating the term…
Abstract
Methods for purging stem cell products of tumor cells and for treating an individual having a disease which is treated by myeloablative therapy and stem cell rescue using a purged product are provided.
Claims52
A method of purging tumor cells from a hematopoietic stem cell product (SCP) having from approximately 2×107 to 3×108 nucleated cells/ml (NC/ml), the method comprising the co-incubation of the stem cell product with a replication-deficient, non-integrating adenovirus (rAd) at a particle number:
- nucleated cell (PN:NC) ratio of approximately 2,500:1 to 250,000:1 for approximately 4 to 24 hours.
A method of treating an individual having a disease which is treated by myeloablative therapy and stem cell rescue using a purged product, the method comprising (a) removing a hematopoietic stem cell product from a patient in need of such treatment, (b) purging the stem cell product using a replication-deficient, non-integrating adenovirus to generate a purged product, wherein the purging comprises the co-incubation of approximately 2×107 to 3×108 nucleated cells/ml (NC/ml) from the stem cell product with a replication-deficient, non-integrating adenovirus at a PN:NC ratio of approximately 2,500:1 to 250,000:1 for approximately 4 to 24 hours, and (c) reinfusing the purged product of (b) into the patient.
A mixture comprising approximately 2×107 to 3×108 nucleated cells/ml (NC/ml) from a hematopoietic stem cell product (SCP) and a replication-deficient, non-integrating adenovirus (rAd) at a PN:NC ratio of approximately 2,500:1 to 250,000:1.
Dependencies are inferred from the claim text.